18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias

Journal of Nuclear Medicine

Volumn 55, Issue 12, 2014, Pages 1959-1965

  O'Brien, John T ^a,b   Firbank, Michael J ^b,c   Davison, Christopher ^b   Barnett, Nicky ^b   Bamford, Claire ^d   Donaldson, Cam ^d,e   Olsen, Kirsty ^b   Herholz, Karl ^f   Williams, David ^b   Lloyd, Jim ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

18F FDG PET; Alzheimer's disease; Dementia with Lewy bodies; Diagnosis; HMPAO SPECT; Sensitivity; Specificity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MALE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTCENTRAL GYRUS; POSTERIOR CINGULATE; PRECUNEUS; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; AGED; BRAIN; COMPARATIVE STUDY; DIAGNOSTIC USE; NEUROPSYCHOLOGICAL TEST; PERFUSION; PROCEDURES; PROSPECTIVE STUDY; PSYCHOLOGY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84915798493     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.143347     Document Type: Article

References (31)

1. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17:1236-1248.
2. Dementia NICE. Supporting people with dementia and their carers in health and social care. National Institute for Health and Care Excellence website http://www.nice.org.uk/cg42. Accessed September 29, 2014.
3. Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257-262.
4. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry. 2011;26:991-999.
5. Yeo JM, Lim XX, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci. 2013;263:539-552.
6. Durand-Martel P, Tremblay D, Brodeur C, Paquet N. Autopsy as gold standard in FDG-PET studies in dementia. Can J Neurol Sci. 2010;37:336-342.
7. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091-2105.
8. 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004;12:554-570.
9. Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127.
10. Davison CM, O'Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry. 2014;29:551-561.
11. Herholz K, Schopphoff H, Schmidt M, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med. 2002;43:21-26.
12. Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med. 2004;18:447-451.
13. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746.
14. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
16. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863-1872.
17. Roth M, Huppert FA, Mountjoy CQ, Tym E. CAMDEX-R: Revised Cambridge Examination for Mental Disorders of the Elderly. Cambridge, U.K.: Cambridge University Press; 1999.
18. Schmidt M. Rey Auditory Verbal Learning Test: A Handbook. Los Angeles, CA: Western Psychological Services; 1996.
19. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.
20. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271-284.
21. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
22. Walker MP, Ayre GA, Cummings JL, et al. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Br J Psychiatry. 2000;177:252-256.
23. Fahn S, Elton R. Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol. 2. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-163, 293-304.
24. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-289.
25. Dorfman DD, Berbaum KS, Metz CE. ROC rating analysis: generalization to the population of readers and cases with the jackknife method. Invest Radiol. 1992;27:723-731.
26. 18F-FDG PET cingulate island sign and comparison to 123I-b-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638-1645.
27. Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395-2404.
28. Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of Tc-99m-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615-622.
29. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with I-123-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
30. Kemp PM, Hoffmann SA, Tossici-Bolt L, Fleming JS, Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun. 2007;28:451-456.
31. O'Brien JT, Oertel WH, McKeith IG, et al. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open. 2014;4:e005122.